Property:Results during intervention
This is a property of type Text.
F
Freedland et al. (2020): A Randomized Controlled Trial of a 6-month low carbohydrate intervention on disease progression in men with recurrent prostate cancer: Carbohydrate and Prostate Study 2 (CAPS2) +
NA +
G
Ghoreishi et al. (2007): Effect of vitamin E on chemotherapy-induced mucositis and neutropenia in leukemic patients undergoing bone marrow transplantation +
NA +
Ghoreishi et al. (2007): Effect of vitamin E on chemotherapy-induced mucositis and neutropenia in leukemic patients undergoing bone marrow transplantation +
NA +
Goossens et al. (2016): Phase III randomised chemoprevention study with selenium on the recurrence of non-invasive urothelial carcinoma. The SELEnium and BLAdder cancer Trial +
NA +
Goossens et al. (2016): Phase III randomised chemoprevention study with selenium on the recurrence of non-invasive urothelial carcinoma. The SELEnium and BLAdder cancer Trial +
NA +
Goossens et al. (2016): Phase III randomised chemoprevention study with selenium on the recurrence of non-invasive urothelial carcinoma. The SELEnium and BLAdder cancer Trial +
NA +
Gorgu et al. (2013): The effect of zinc sulphate in the prevention of radiation induced oral mucositis in patents with head and neck cancer +
Post‐treatment serum zinc levels were signifiicantly lower in the control group than in the treatment group (p = 0.05) +
Gorgu et al. (2013): The effect of zinc sulphate in the prevention of radiation induced oral mucositis in patents with head and neck cancer +
No statistical relationship between the administration of zinc and esophagitis (p = 0.596);
incidence of esophagitis was lower in the patients with normal serum zinc levels before and after RT, but that was not statistically signifiicant (p = 0.351) +
Gorgu et al. (2013): The effect of zinc sulphate in the prevention of radiation induced oral mucositis in patents with head and neck cancer +
Grade 0, 1, 2, and 3 mucositis were observed in 37.5%, 32.5%, 27.5%, and 2.5% of the patients; Grade 4 mucositis was not noted in any of the patients;
there was no relationship between zinc replacement and mucositis (p = 0.159);
incidence of mucositis was lower in the patients with normal serum zinc levels before and after RT, though that was not statistically signifiicant (p = 0.476) +
Grimison et al. (2020): Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial +
Results after 2 cycles, after switching to the other arm:
* Advantage for intervention arm for percentage for CR (p=0.04), for scales "no vomiting" (p=0.05), "no emergency medication" p=0.04), "no significant nausea" (p=0.03), mean and maximum number of vomiting per day (p=0.003, p=0.001), mean/maximum nausea values (p's<0.001).
* No difference for complete response and "no significant nausea" (p=0.12) +
Grimison et al. (2020): Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial +
Moderate or severe cannabinoid-related side effects in intervention arm (31%) and placebo arm (7%) (p=0.002):
* Significant differences for sedation (19% vs. 4%, p=0.002), dizziness (10% vs. 1%, p=0.03)
* No differences for disorientation (3% vs. 0%, p=0.5), anxiety (1% vs. 1%, p=1.00)
* No cannabinoid-related serious adverse events were reported.
83% of the participants preferred cannabis over placebo and 15% had a preference for placebo (p<0.001). +
Grimison et al. (2020): Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial +
FLIE:
* significant advantage for intervention arm for nausea scale (mean difference: 20.9 on 100-point scale, p < 0.001) and vomiting scale (mean difference: 11.9, p < 0.001)
AQOL-8D:
* significant advantage for intervention arm in use-related QoL (mean difference: 0.04, 95% CI 0.01,0.07; p=0.019)
* physical health (mean difference: 0.06, 95% CI 0.03-0.09, p < 0.001)
* mental health (mean difference: 0.04, 95% CI 0.01, 0.06, p=0.004)
* pain (mean difference: 0.08, 95% CI 0.03, 0.13, p=0.003) +
Grimison et al. (2020): Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial +
Results after 2 cycles, after switching to the other arm:
* Significant advantage for intervention arm (25%) compared to placebo arm (14%): RR=1.77; 90% CI=1.12,2.79; p=0.041. +
Gujral et al. (2001): Efficacy of hydrolytic enzymes in preventing radiation therapy-induced side effects in patients with head and neck cancers +
NI +
Gujral et al. (2001): Efficacy of hydrolytic enzymes in preventing radiation therapy-induced side effects in patients with head and neck cancers +
NI +
Gujral et al. (2001): Efficacy of hydrolytic enzymes in preventing radiation therapy-induced side effects in patients with head and neck cancers +
NI +
Gujral et al. (2001): Efficacy of hydrolytic enzymes in preventing radiation therapy-induced side effects in patients with head and neck cancers +
NI +
Gujral et al. (2001): Efficacy of hydrolytic enzymes in preventing radiation therapy-induced side effects in patients with head and neck cancers +
NA +